Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

4.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
4.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

2.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.

Nature cancer·2026
Same author

Functionally heterogeneous intratumoral CD4<sup>+</sup>CD8<sup>+</sup> double-positive T cells can give rise to single-positive T cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases.

Science advances·2025
Same author

Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.

Blood·2025
Same author

PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSE.

bioRxiv : the preprint server for biology·2025
Same author

Tumor cell heterogeneity drives spatial organization of the intratumoral immune response.

The Journal of experimental medicine·2025
Same journal

Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

The Journal of experimental medicine·2026
Same journal

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same journal

Flawed translation triggers oncogenic B-T cell communication.

The Journal of experimental medicine·2026
Same journal

Correction: LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated.

The Journal of experimental medicine·2026
Same journal

Mechanobiology of inflammation: Pulling the strings of innate immunity.

The Journal of experimental medicine·2026
Same journal

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

The Journal of experimental medicine·2026
See all related articles

Related Experiment Video

Updated: Sep 12, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K

CD4+ T cell dysfunction in cancer.

Hrishi Venkatesh1, Lawrence Fong1

  • 1Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center , Seattle, WA, USA.

The Journal of Experimental Medicine
|August 7, 2025
PubMed
Summary
This summary is machine-generated.

CD4+ T cells are crucial for anti-tumor immunity, but their function is impaired in tumors. Understanding and counteracting these changes can improve cancer immunotherapy effectiveness.

More Related Videos

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

22.8K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K

Related Experiment Videos

Last Updated: Sep 12, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

22.8K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K

Area of Science:

  • Immunology
  • Cancer Research
  • Cellular Biology

Background:

  • CD8+ T cells are vital for cancer immunotherapy.
  • CD4+ T cells are increasingly recognized for their role in anti-tumor immunity.
  • Mechanisms of CD4+ T cell functional impairment in tumors are less understood than for CD8+ T cells.

Purpose of the Study:

  • To review alterations in CD4+ T cells within tumor-bearing hosts.
  • To compare these alterations with those in CD8+ T cells.
  • To discuss the impact of these changes on tumor control and immunotherapy efficacy.

Main Methods:

  • Literature review of studies on T cell function in cancer.
  • Comparative analysis of CD4+ and CD8+ T cell alterations in tumor microenvironments.
  • Synthesis of current knowledge on mechanisms of T cell dysfunction.

Main Results:

  • CD4+ T cells exhibit functional impairments in tumors, distinct from CD8+ T cells.
  • These impairments can involve altered cytokine production, metabolic changes, and reduced effector functions.
  • The specific mechanisms of CD4+ T cell dysfunction in tumors require further elucidation.

Conclusions:

  • Targeting CD4+ T cell dysfunction is a promising strategy to enhance cancer immunotherapy.
  • Further research into the mechanisms of CD4+ T cell impairment is needed.
  • Restoring CD4+ T cell function may significantly improve anti-tumor responses and patient outcomes.